NR546 ADVANCED PHARMACOLOGY PSYCHOPHARMACOLOGY
MIDTERM EXAM CHAMBERLAIN ACTUAL 2026/2027 - COMPLETE
QUESTIONS WITH DETAILED RATIONALES 100% VERIFIED ANSWERS -
180 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Evaluate the pharmacodynamic and pharmacokinetic profiles of psychotropic agents
2 Analyze drug-drug interactions and adverse effect profiles in complex clinical scenarios
3 Apply evidence-based guidelines to optimize psychopharmacologic treatment
4 Synthesize knowledge of neurobiology to predict therapeutic and toxic effects
5 NR546 Advanced Pharmacology Psychopharmacology Midterm Exam Chamberlain Actual 2026
6 2027
7 Complete Questions with Detailed Rationales 100% Verified Answers
8 Pass Guaranteed
9 A+ Graded
10 Foundations of Advanced Pharmacology Psychopharmacology
11 Applied Advanced Pharmacology Psychopharmacology
12 Advanced Advanced Pharmacology Psychopharmacology
13 Advanced Pharmacology Psychopharmacology Review
Page 1
,Q1 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient on long-term fluoxetine is prescribed linezolid for a multidrug-resistant
infection. What is the most critical pharmacodynamic interaction and its
recommended management?
A. Additive QT prolongation; monitor ECG and discontinue fluoxetine if QTc exceeds 500 ms.
B. Serotonin syndrome due to MAO-A inhibition; discontinue fluoxetine for at least 5 weeks
before starting linezolid. CORRECT
C. Reduced linezolid efficacy due to CYP2D6 inhibition; increase linezolid dose.
D. Hypertensive crisis from tyramine potentiation; restrict dietary tyramine and monitor blood
pressure.
RATIONALE: Linezolid is a reversible non-selective MAO inhibitor, and concurrent use with
fluoxetine (a potent serotonin reuptake inhibitor) poses a high risk of serotonin syndrome.
Because fluoxetine has a long half-life (norfluoxetine), it must be discontinued at least 5 weeks
prior to initiating linezolid. Additive QT prolongation (A) is not the primary interaction; linezolid
does not rely on CYP2D6 (C); hypertensive crisis (D) is more relevant to tyramine-containing
foods, not fluoxetine.
Q2 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with bipolar I disorder is stabilized on lithium but has breakthrough
depressive episodes. Which augmentation strategy is most supported by current
evidence and has a favorable risk-benefit profile?
A. Add lamotrigine and titrate slowly to target dose of 200 mg/day. CORRECT
B. Add aripiprazole 10 mg/day for its antidepressant properties.
C. Switch lithium to valproate to improve mood stability.
D. Add an SSRI such as paroxetine to address the depressive episode.
RATIONALE: Lamotrigine is FDA-approved for maintenance of bipolar disorder, particularly for
depressive episodes, and is a recommended adjunct to lithium. Aripiprazole (B) is more effective
for mania, not depression. Valproate (C) is primarily antimanic. SSRIs like paroxetine (D) carry a
risk of mood switching and are not first-line in bipolar depression, especially without a mood
stabilizer.
Page 2
,Q3 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with schizophrenia has persistent negative symptoms despite adequate
antipsychotic therapy. Which of the following medications is most likely to
improve negative symptoms through its unique receptor profile?
A. Haloperidol, by potent D2 antagonism in the mesocortical pathway.
B. Clozapine, by combined 5-HT2A and D2 antagonism with high affinity for D4 and alpha-2
receptors. CORRECT
C. Risperidone, due to its high D2 occupancy at low doses.
D. Fluphenazine, because of its high potency and long-acting formulation.
RATIONALE: Clozapine is uniquely effective for treatment-resistant schizophrenia and negative
symptoms, attributed to its broad receptor profile including 5-HT2A, D4, and alpha-2 antagonism,
which enhances dopamine and norepinephrine release in prefrontal cortex. Haloperidol (A) and
fluphenazine (D) are typical antipsychotics with limited effect on negative symptoms. Risperidone
(C) at high doses may worsen negative symptoms due to increased D2 occupancy.
Q4 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with generalized anxiety disorder has been on sertraline for 6 weeks with
partial response. Which of the following strategies is most appropriate to optimize
treatment?
A. Discontinue sertraline and start buspirone monotherapy.
B. Increase sertraline dose to the maximum recommended and reassess in 2-4 weeks.
CORRECT
C. Add a benzodiazepine for long-term adjunctive use.
D. Switch to paroxetine because it has a faster onset of action.
RATIONALE: SSRIs like sertraline may require up to 8-12 weeks at therapeutic doses for full
effect; dose optimization is the first step after partial response. Buspirone (A) is less effective for
GAD as monotherapy after SSRI failure. Benzodiazepines (C) are not recommended for
long-term use due to dependence. Paroxetine (D) has a similar onset, and switching is not
indicated before dose optimization.
Page 3
, Q5 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with major depressive disorder is started on phenelzine. Which dietary
restriction is most critical to prevent a hypertensive crisis?
A. Avoid foods high in tyramine, such as aged cheeses and cured meats. CORRECT
B. Limit caffeine intake to less than 200 mg/day.
C. Avoid foods high in tryptophan, such as turkey and milk.
D. Restrict sodium intake to prevent fluid retention.
RATIONALE: Phenelzine is a non-selective irreversible MAO inhibitor; tyramine-rich foods can
cause massive norepinephrine release, leading to hypertensive crisis. Caffeine (B) is not the
primary concern. Tryptophan (C) is relevant to serotonin syndrome but not hypertensive crisis.
Sodium restriction (D) is not necessary.
Q6 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with attention-deficit/hyperactivity disorder is being treated with
methylphenidate. Which of the following adverse effects is most likely to limit its
use in a patient with a history of cardiac arrhythmias?
A. Insomnia and appetite suppression.
B. Elevation of blood pressure and heart rate. CORRECT
C. Hepatotoxicity with prolonged use.
D. Development of tics or exacerbation of Tourette syndrome.
RATIONALE: Methylphenidate increases sympathetic tone, causing dose-dependent increases in
blood pressure and heart rate, which can precipitate arrhythmias in susceptible patients.
Insomnia (A) and tics (D) are common but less dangerous. Hepatotoxicity (C) is not a known
adverse effect of methylphenidate.
Page 4
MIDTERM EXAM CHAMBERLAIN ACTUAL 2026/2027 - COMPLETE
QUESTIONS WITH DETAILED RATIONALES 100% VERIFIED ANSWERS -
180 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Evaluate the pharmacodynamic and pharmacokinetic profiles of psychotropic agents
2 Analyze drug-drug interactions and adverse effect profiles in complex clinical scenarios
3 Apply evidence-based guidelines to optimize psychopharmacologic treatment
4 Synthesize knowledge of neurobiology to predict therapeutic and toxic effects
5 NR546 Advanced Pharmacology Psychopharmacology Midterm Exam Chamberlain Actual 2026
6 2027
7 Complete Questions with Detailed Rationales 100% Verified Answers
8 Pass Guaranteed
9 A+ Graded
10 Foundations of Advanced Pharmacology Psychopharmacology
11 Applied Advanced Pharmacology Psychopharmacology
12 Advanced Advanced Pharmacology Psychopharmacology
13 Advanced Pharmacology Psychopharmacology Review
Page 1
,Q1 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient on long-term fluoxetine is prescribed linezolid for a multidrug-resistant
infection. What is the most critical pharmacodynamic interaction and its
recommended management?
A. Additive QT prolongation; monitor ECG and discontinue fluoxetine if QTc exceeds 500 ms.
B. Serotonin syndrome due to MAO-A inhibition; discontinue fluoxetine for at least 5 weeks
before starting linezolid. CORRECT
C. Reduced linezolid efficacy due to CYP2D6 inhibition; increase linezolid dose.
D. Hypertensive crisis from tyramine potentiation; restrict dietary tyramine and monitor blood
pressure.
RATIONALE: Linezolid is a reversible non-selective MAO inhibitor, and concurrent use with
fluoxetine (a potent serotonin reuptake inhibitor) poses a high risk of serotonin syndrome.
Because fluoxetine has a long half-life (norfluoxetine), it must be discontinued at least 5 weeks
prior to initiating linezolid. Additive QT prolongation (A) is not the primary interaction; linezolid
does not rely on CYP2D6 (C); hypertensive crisis (D) is more relevant to tyramine-containing
foods, not fluoxetine.
Q2 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with bipolar I disorder is stabilized on lithium but has breakthrough
depressive episodes. Which augmentation strategy is most supported by current
evidence and has a favorable risk-benefit profile?
A. Add lamotrigine and titrate slowly to target dose of 200 mg/day. CORRECT
B. Add aripiprazole 10 mg/day for its antidepressant properties.
C. Switch lithium to valproate to improve mood stability.
D. Add an SSRI such as paroxetine to address the depressive episode.
RATIONALE: Lamotrigine is FDA-approved for maintenance of bipolar disorder, particularly for
depressive episodes, and is a recommended adjunct to lithium. Aripiprazole (B) is more effective
for mania, not depression. Valproate (C) is primarily antimanic. SSRIs like paroxetine (D) carry a
risk of mood switching and are not first-line in bipolar depression, especially without a mood
stabilizer.
Page 2
,Q3 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with schizophrenia has persistent negative symptoms despite adequate
antipsychotic therapy. Which of the following medications is most likely to
improve negative symptoms through its unique receptor profile?
A. Haloperidol, by potent D2 antagonism in the mesocortical pathway.
B. Clozapine, by combined 5-HT2A and D2 antagonism with high affinity for D4 and alpha-2
receptors. CORRECT
C. Risperidone, due to its high D2 occupancy at low doses.
D. Fluphenazine, because of its high potency and long-acting formulation.
RATIONALE: Clozapine is uniquely effective for treatment-resistant schizophrenia and negative
symptoms, attributed to its broad receptor profile including 5-HT2A, D4, and alpha-2 antagonism,
which enhances dopamine and norepinephrine release in prefrontal cortex. Haloperidol (A) and
fluphenazine (D) are typical antipsychotics with limited effect on negative symptoms. Risperidone
(C) at high doses may worsen negative symptoms due to increased D2 occupancy.
Q4 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with generalized anxiety disorder has been on sertraline for 6 weeks with
partial response. Which of the following strategies is most appropriate to optimize
treatment?
A. Discontinue sertraline and start buspirone monotherapy.
B. Increase sertraline dose to the maximum recommended and reassess in 2-4 weeks.
CORRECT
C. Add a benzodiazepine for long-term adjunctive use.
D. Switch to paroxetine because it has a faster onset of action.
RATIONALE: SSRIs like sertraline may require up to 8-12 weeks at therapeutic doses for full
effect; dose optimization is the first step after partial response. Buspirone (A) is less effective for
GAD as monotherapy after SSRI failure. Benzodiazepines (C) are not recommended for
long-term use due to dependence. Paroxetine (D) has a similar onset, and switching is not
indicated before dose optimization.
Page 3
, Q5 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with major depressive disorder is started on phenelzine. Which dietary
restriction is most critical to prevent a hypertensive crisis?
A. Avoid foods high in tyramine, such as aged cheeses and cured meats. CORRECT
B. Limit caffeine intake to less than 200 mg/day.
C. Avoid foods high in tryptophan, such as turkey and milk.
D. Restrict sodium intake to prevent fluid retention.
RATIONALE: Phenelzine is a non-selective irreversible MAO inhibitor; tyramine-rich foods can
cause massive norepinephrine release, leading to hypertensive crisis. Caffeine (B) is not the
primary concern. Tryptophan (C) is relevant to serotonin syndrome but not hypertensive crisis.
Sodium restriction (D) is not necessary.
Q6 EVALUATE THE PHARMACODYNAMIC AND PHARMACOKINETIC PROFILES OF
PSYCHOTROPIC AGENTS
A patient with attention-deficit/hyperactivity disorder is being treated with
methylphenidate. Which of the following adverse effects is most likely to limit its
use in a patient with a history of cardiac arrhythmias?
A. Insomnia and appetite suppression.
B. Elevation of blood pressure and heart rate. CORRECT
C. Hepatotoxicity with prolonged use.
D. Development of tics or exacerbation of Tourette syndrome.
RATIONALE: Methylphenidate increases sympathetic tone, causing dose-dependent increases in
blood pressure and heart rate, which can precipitate arrhythmias in susceptible patients.
Insomnia (A) and tics (D) are common but less dangerous. Hepatotoxicity (C) is not a known
adverse effect of methylphenidate.
Page 4
